MRC Technology, EMBLEM in Drug Development Pact

MRC Technology has entered into a strategic collaboration with EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) to identify novel drug targets in the field of small molecules and antibodies. The companies will work together to fast track targets through drug discovery with the goal of creating potent and selective novel therapeutics. The agreement combines EMBLEM’s experience in supporting academics with MRC’s expertise in translating novel biology targets into lead stage therapeutic assets.
 
Dr. Dave Tapolczay, MRC Technology’s chief executive officer, said, “Heidelberg is a world center for academic research and we are delighted to be collaborating with EMBLEM, and researchers from the EMBL Chemical Biology group. The skills of the two organizations are highly complementary, and the initiative further strengthens MRC Technology’s academic drug development and commercialization network – ultimately working towards improving the rate at which academic research is translated into new medicines.”
 
EMBLEM’s managing director, Dr. Gábor Lamm, said “We work closely with a network of partners to develop technologies to a sufficient level of maturity such that they can be transferred to industry. We look forward to working with MRC Technology to identify projects for collaborative screening and further development.”